CNS Therapeutics develops pharmaceuticals for the treatment of neurological disorders and chronic pain.
Business Model:
Revenue: $17.7M
Employees: 51-200
CNS Therapeutics was acquired by
Mallinckrodt.
The acquisition happend on 2012-09-24.
Details of the transaction were not public
Address: 332 Minnesota St
City: Saint Paul
State: MN
Zip: 55101
Country: US
CNS Therapeutics is a private company based in St. Paul, Minn. CNS Therapeutics develops and markets safe, high-quality pharmaceuticals for site-specific delivery to the central nervous system to treat neurological disorders and chronic pain. In addition to its first FDA-approved product, Gablofen, CNS Therapeutics is currently collaborating with U.S. and international scientific experts to develop and test new treatments for pain and Parkinson&s;s disease.
Contact Phone:
+16512076959
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 12/2012 | Venture Round | $3M | 8/2009 | Venture Round | $7M |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|